Search research articles
Contact Us
Filters
Showing results (301-310 of 419) with videos related to
Page
of 42
Sort By:
Cancer
|
September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R Feldman, Yasser Ged, Chung-Han Lee, et al.
Urologic Oncology
|
April 15, 2017
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy
Daniel M Tennenbaum, Brandon J Manley, Emily Zabor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M H Voss, A Hussain, N Vogelzang, et al.
Journal for Immunotherapy of Cancer
|
December 29, 2018
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
A Boilève, M I Carlo, P Barthélémy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Elio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Mehmet A Bilen, Brian I Rini, Martin H Voss, et al.
European Urology
|
February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Maria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I Rini, Dena Battle, Robert A Figlin, et al.
European Urology Oncology
|
November 27, 2025
Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma
Yash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Page
of 42
Search research articles
Search
Showing results (301-310 of 419) with videos related to
Sort By:
Page
of 42
Cancer
|
September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R Feldman, Yasser Ged, Chung-Han Lee, et al.
Urologic Oncology
|
April 15, 2017
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy
Daniel M Tennenbaum, Brandon J Manley, Emily Zabor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M H Voss, A Hussain, N Vogelzang, et al.
Journal for Immunotherapy of Cancer
|
December 29, 2018
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
A Boilève, M I Carlo, P Barthélémy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Elio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Mehmet A Bilen, Brian I Rini, Martin H Voss, et al.
European Urology
|
February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Maria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I Rini, Dena Battle, Robert A Figlin, et al.
European Urology Oncology
|
November 27, 2025
Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma
Yash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Page
of 42